行情

ONTX

ONTX

Onconova医疗
NASDAQ

实时行情|Nasdaq Last Sale

0.5444
+0.0095
+1.78%
盘后: 0.5299 -0.0145 -2.66% 18:59 02/20 EST
开盘
0.5400
昨收
0.5349
最高
0.5900
最低
0.5301
成交量
2,197.47万
成交额
--
52周最高
4.826
52周最低
0.1027
市值
7,552.45万
市盈率(TTM)
-0.1500
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ONTX 新闻

  • Onconova Therapeutics, Inc. (ONTX) Shares March Higher, Can It Continue?
  • Zacks.10小时前
  • US Dollar Flexes Muscles Against Other Currencies: 5 Winners
  • Zacks.12小时前
  • The Zacks Analyst Blog Highlights: Apple, Eagle Bancorp Montana, Onconova Therapeutics, Proteostasis Therapeutics and Abeona Therapeutics
  • Zacks.1天前
  • Coronavirus to Hit Apple Sales: Invest in Domestic Producers
  • Zacks.2天前

更多

所属板块

制药
-0.54%
制药与医学研究
-0.40%

热门股票

名称
价格
涨跌幅

ONTX 简况

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company's lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib.
展开

Webull提供Onconova Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。